Webinar recap
This webinar followed a 178-bed community hospital through its move from trough-based vancomycin monitoring to AUC-guided dosing with Bayesian software, in line with the 2020 consensus guidelines that recommend AUC monitoring for serious MRSA infections.
The hospital’s clinical pharmacy team evaluated several calculators before choosing InsightRX, citing the ability to estimate AUC from a single level, to interpret levels drawn before steady state, and to dose patients with obesity more accurately. Implementation ran through a pharmacist-managed protocol approved by the pharmacy and therapeutics committee, with super-users trained first, then individual competency assessments for the full pharmacist staff.
A retrospective comparison of 256 patients dosed by AUC against 200 historical patients dosed by trough showed clear gains. Appropriately timed levels rose from 70% to 97%, and 72% of patients reached a therapeutic AUC, compared with 29% reaching a therapeutic trough under the old protocol. Most levels moved to morning lab draws, easing the workload for laboratory staff and for overnight pharmacists.
The team also shared what the data taught them. Pharmacists tended to choose regimens predicting AUCs near the bottom of the 400 to 600 mg·h/L range, so the team began targeting initial AUCs closer to 500. Treatment tags for special populations showed strong results in patients with obesity, and pointed to under-dosing in patients with low muscle mass and in younger patients with excellent renal function.
